Our collaboration w/Pieris Pharmaceuticals $PIRS gets a nice shot in the arm with half of their market cap being paid cash up front to them, in a collaboration of their own with Servier, a pharmaceutical company headquartered in France....annual sales EUR4 Billion and 5 products to date in late pre-clinical or early development in immuno-oncology.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.